<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0036-3634</journal-id>
<journal-title><![CDATA[Salud Pública de México]]></journal-title>
<abbrev-journal-title><![CDATA[Salud pública Méx]]></abbrev-journal-title>
<issn>0036-3634</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud Pública]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0036-36342006000600008</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Lactobacillus casei ssp. rhamnosus enhances non specific protection against Plasmodium chabaudi AS in mice]]></article-title>
<article-title xml:lang="es"><![CDATA[Lactobacillus casei ssp. rhamnosus aumenta la protección no específica contra Plasmodium chabaudi AS en ratones]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Gómez]]></surname>
<given-names><![CDATA[Federico]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ixta-Rodríguez]]></surname>
<given-names><![CDATA[Olga]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguilar-Figueroa]]></surname>
<given-names><![CDATA[Blanca]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Cruz]]></surname>
<given-names><![CDATA[Ranulfo]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Monroy-Ostria]]></surname>
<given-names><![CDATA[Amalia]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Instituto Politécnico Nacional Escuela Nacional de Ciencias Biológicas Departamento de Parasitología]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Instituto Nacional de Virología Secretaría de Salud ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A03">
<institution><![CDATA[,Instituto Politécnico Nacional Escuela Nacional de Ciencias Biológicas Departamento de Inmunología]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2006</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2006</year>
</pub-date>
<volume>48</volume>
<numero>6</numero>
<fpage>498</fpage>
<lpage>503</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0036-36342006000600008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0036-36342006000600008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0036-36342006000600008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[OBJECTIVE: To evaluate the capacity of Lactobacillus casei ssp. rhamnosus to enhance resistance against Plasmodium chabaudi chabaudi AS. MATERIAL AND METHODS: NIH mice were IP injected with viable lactobacillus casei seven days (LC1 group) or 7 and 14 days (LC2 group) before the challenge (day 0) with Plasmodium chabaudi parasitized red blood cells (pRBC). Control mice were inoculated with pRBC only. When parasitaemia was resolved, naive mice were injected with spleen cells from each group. The parasitaemia was measured. Nitric oxide (NO.) in serum was determined. RESULTS: Mice from the LC1 group presented a reduction in parasitaemia, with a prepatent period of five days, parasitaemia lasted 11 days, and the peak was (36.3 % pRBC) on the 12th day post-infection. Mice from the LC2 group showed a prepatent period of five days, parasitaemia lasted eight days, and the peak (30 % pRBC) was of on the 11th day. In the control, the prepatent period was three days, the parasitaemia lasted 15 days, and the peak (51% pRBC) was on day nine. Mice inoculated with spleen cells from the LC2 group showed a prepatent period of 21 days, parasitaemia lasted seven days, and the peak (13.5% pRBC) was on the 26th day. CONCLUSION: L. casei enhanced nonspecific resistance to P. chabaudi, as indicated by longer prepatent periods, reduced parasitaemia, and reduction in the viability of the parasites recovered from the spleen of infected mice, along with high concentrations of NO. in serum.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[OBJETIVO: Evaluar la capacidad de Lactobacillus casei de aumentar la resistencia a la infección con Plasmodium chabaudi en ratones. MATERIAL Y MÉTODOS: Ratones NIH fueron inyectados intraperitonealmente con L. casei viable 7 días (grupo LC1) o 7 y 14 días (grupo LC2) antes del reto (día 0) con glóbulos rojos parasitados (GRP) con P. chabaudi. Los testigos fueron inoculados con GRP solamente. Cuando la parasitemia se resolvió, se inocularon ratones limpios con células de bazo de cada grupo. Se midió la concentración de óxido nítrico (NO.) en suero. RESULTADOS: El grupo LC1 presentó un periodo prepatente de 5 días, una parasitemia de 11 días con el máximo (36.3% de GRP) el día 12. Los ratones del grupo LC2 mostraron un periodo prepatente de 5 días, una parasitemia de 8 días con el pico (30% de GRI) el día 11. En los testigos el periodo prepatente fue de 3 días, la parasitemia de 15 y su máximo (51% de GRI) el día 9. Los ratones que recibieron células de bazo del grupo LC2, mostraron un período prepatente de 21 días, una parasitemia de 7 con su máximo (13.5% de GRI) el día 26. CONCLUSIÓN: L. casei aumenta la resistencia no específica hacia P. chabaudi a juzgar por los periodos prepatentes más largos, las bajas parasitemias, la reducción en la viabilidad y la elevación de la concentración de NO. en el suero, que presentaron los ratones estimulados con lactobacilos.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[lactic acid bacteria]]></kwd>
<kwd lng="en"><![CDATA[probiotics]]></kwd>
<kwd lng="en"><![CDATA[non specific protection]]></kwd>
<kwd lng="en"><![CDATA[Plasmodium chabaudi infection]]></kwd>
<kwd lng="en"><![CDATA[Lactobacillus casei]]></kwd>
<kwd lng="en"><![CDATA[immunity]]></kwd>
<kwd lng="en"><![CDATA[natural]]></kwd>
<kwd lng="en"><![CDATA[Plasmodium chabaudi]]></kwd>
<kwd lng="es"><![CDATA[bacterias lácticas]]></kwd>
<kwd lng="es"><![CDATA[probióticos]]></kwd>
<kwd lng="es"><![CDATA[protección no específica]]></kwd>
<kwd lng="es"><![CDATA[infección con Plasmodium chabaudi]]></kwd>
<kwd lng="es"><![CDATA[Lactobacillus casei]]></kwd>
<kwd lng="es"><![CDATA[inmunidad natural]]></kwd>
<kwd lng="es"><![CDATA[Plasmodium chabaudi]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2" face="Verdana"><b>ART&Iacute;CULO ORIGINAL</b></font></p>     <p>&nbsp;</p>     <p><font size="4" face="verdana"> <b><i>Lactobacillus casei</i> ssp. <i>rhamnosus</i>    enhances non specific protection against <i>Plasmodium chabaudi</i> AS in mice</b></font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b><I>Lactobacillus casei </I>ssp.<I> rhamnosus    </I>aumenta la protecci&oacute;n no espec&iacute;fica contra <I>Plasmodium chabaudi    </I>AS en ratones</b></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><b>Federico Mart&iacute;nez-G&oacute;mez, Dr    en C<sup>I</sup>; Olga Ixta-Rodr&iacute;guez, QBP<sup>I</sup>; Blanca Aguilar-Figueroa,    M en C<sup>I</sup>; Ranulfo Hern&aacute;ndez-Cruz, QBP<sup>II</sup>; Amalia    Monroy-Ostria, Dra en C<SUP>III</SUP></b></font></p>     <p><font size="2" face="Verdana"><sup>I</sup>Departamento de Parasitolog&iacute;a,    Escuela Nacional de Ciencias Biol&oacute;gicas, Instituto Polit&eacute;cnico    Nacional    <br>   <sup>II</sup>Instituto Nacional de Virolog&iacute;a, Secretar&iacute;a de Salud    ]]></body>
<body><![CDATA[<br>   <sup>III</sup>Departamento de Inmunolog&iacute;a, Escuela Nacional de Ciencias    Biol&oacute;gicas, Instituto Polit&eacute;cnico Nacional</font></p>     <p>&nbsp;</p>     <p>&nbsp;</p> <hr size="1" noshade>     <p><font size="2" face="Verdana"><B>ABSTRACT</B></font></p>     <p><font size="2" face="Verdana"><b>OBJECTIVE:</b> To evaluate the capacity of    <I>Lactobacillus casei</I> ssp.<I> rhamnosus</I> to enhance resistance against    <I>Plasmodium chabaudi chabaudi </I>AS.    <br>   <b>MATERIAL AND METHODS:</b> NIH mice were IP injected with viable <I>lactobacillus casei</I> seven days (LC1 group) or 7 and 14 days (LC2 group) before the    challenge (day 0) with <I>Plasmodium chabaudi</I> parasitized red blood cells    (pRBC). Control mice were inoculated with pRBC only. When parasitaemia was resolved,    naive mice were injected with spleen cells from each group. The parasitaemia    was measured. Nitric oxide (NO<sup>.</sup>) in serum was determined.    <br>   <b>RESULTS:</b> Mice from the LC1 group presented a reduction in parasitaemia,    with a prepatent period of five days, parasitaemia lasted 11 days, and the peak    was (36.3 % pRBC) on the 12<SUP>th</SUP> day post-infection. Mice from the LC2    group showed a prepatent period of five days, parasitaemia lasted eight days,    and the peak (30 % pRBC) was of on the 11<SUP>th</SUP> day. In the control,    the prepatent period was three days, the parasitaemia lasted 15 days, and the    peak (51% pRBC) was on day nine. Mice inoculated with spleen cells from the    LC2 group showed a prepatent period of 21 days, parasitaemia lasted seven days,    and the peak (13.5% pRBC) was on the 26<SUP>th</SUP> day.    <br>   <b>CONCLUSION: </b><I>L. casei</I> enhanced nonspecific resistance to <I>P.    chabaudi,</I> as indicated by longer prepatent periods, reduced parasitaemia,    and reduction in the viability of the parasites recovered from the spleen of    infected mice, along with high concentrations of NO<sup>.</sup> in serum. </font></p>     <p><font size="2" face="Verdana"><b>Key words:</b> lactic acid bacteria; probiotics;    non specific protection; <I>Plasmodium chabaudi </I>infection; <I>Lactobacillus    casei</I>; immunity, natural; <I>Plasmodium chabaudi</I></font></p> <hr size="1" noshade>     <p><font size="2" face="Verdana"><b>RESUMEN</b></font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"><b>OBJETIVO:</b> Evaluar la capacidad de <I>Lactobacillus    casei</I> de aumentar la resistencia a la infecci&oacute;n con <I>Plasmodium    chabaudi</I> en ratones.    <br>   <b>MATERIAL Y M&Eacute;TODOS:</b> Ratones NIH fueron inyectados intraperitonealmente    con <I>L. casei </I>viable 7 d&iacute;as (grupo LC1) o 7 y 14 d&iacute;as (grupo    LC2) antes del reto (d&iacute;a 0) con gl&oacute;bulos rojos parasitados (GRP)    con <I>P. chabaudi</I>. Los testigos fueron inoculados con GRP solamente. Cuando    la parasitemia se resolvi&oacute;, se inocularon ratones limpios con c&eacute;lulas    de bazo de cada grupo. Se midi&oacute; la concentraci&oacute;n de &oacute;xido    n&iacute;trico (NO<sup>.</sup>) en suero.    <br>   <b>RESULTADOS:</b> El grupo LC1 present&oacute; un periodo prepatente de 5 d&iacute;as,    una parasitemia de 11 d&iacute;as con el m&aacute;ximo (36.3% de GRP) el d&iacute;a    12. Los ratones del grupo LC2 mostraron un periodo prepatente de 5 d&iacute;as,    una parasitemia de 8 d&iacute;as con el pico (30% de GRI) el d&iacute;a 11.    En los testigos el periodo prepatente fue de 3 d&iacute;as, la parasitemia de    15 y su m&aacute;ximo (51% de GRI) el d&iacute;a 9. Los ratones que recibieron    c&eacute;lulas de bazo del grupo LC2, mostraron un per&iacute;odo prepatente    de 21 d&iacute;as, una parasitemia de 7 con su m&aacute;ximo (13.5% de GRI)    el d&iacute;a 26.    <br>   <B>CONCLUSI&Oacute;N: </B><I>L. casei</I> aumenta la resistencia no espec&iacute;fica    hacia <I>P. chabaudi</I> a juzgar por los periodos prepatentes m&aacute;s largos,    las bajas parasitemias, la reducci&oacute;n en la viabilidad y la elevaci&oacute;n    de la concentraci&oacute;n de NO<sup>.</sup> en el suero, que presentaron los    ratones estimulados con lactobacilos. </font></p>     <p><font size="2" face="Verdana"><b>Palabras clave:</b> bacterias l&aacute;cticas;    probi&oacute;ticos; protecci&oacute;n no espec&iacute;fica; infecci&oacute;n    con <I>Plasmodium chabaudi</I>; <I>Lactobacillus casei</I>: inmunidad natural;    <I>Plasmodium chabaudi</I> </font></p> <hr size="1" noshade>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"> Lactic acid bacteria (LAB) represent a group    of different gram positive microorganisms which are widely used in the dairy    industry because they provide a pleasant flavor in milk products and increase    their nutritional properties. They have also been recognized as probiotic microorganisms    which are defined as mono or mixed cultures of live microorganisms which, when    applied to animal and humans, beneficially affect the host by improving the    properties of the indigenous microflora. There is much information about the    role of probiotic bacteria in the improvement of the intestinal microflora and    the modulation of the immune system.<SUP>1,2,3</SUP> Beneficial effects have    been obtained with mice that received LAB orally,<SUP>4</SUP> via intraperitoneal    (IP),<SUP>5 </SUP>and even via intrapleural.<SUP>6 </SUP>It has been widely    shown that LAB enhance protection and reduce pathological effects against: Shiga    toxin-producing <I>Escherichia coli</I>,<SUP>7 </SUP><I>Salmonella typhim urium,</I><SUP>8,9    </SUP><I>Candida albicans,</I><SUP>10</SUP> rotavirus,<SUP>11</SUP> and even    against helminthic parasites.<SUP>12 </SUP> </font></p>     <p> <font size="2" face="Verdana"><I>Lactobacillus casei</I> enhances protection    against intracellular bacteria by inducing IL-12 and IFN<font face="Symbol">g</font>    production.<SUP>13</SUP> These cytokines play a central role in the innate and    T helper 1 lymphocytes (Th1) immune responses, which is relevant in cancer prevention.<SUP>14</SUP>    The main effectors cells that participate in the innate immune response are    neutrophils, mononuclear cells, and natural killer lymphocytes (NK). </font></p>     <p><font size="2" face="Verdana"> The main sources of IL-12 are activated mononuclear    and dendritic cells. IL-12 is a good stimulator of NK and Th1 lymphocytes for    producing IFN<font face="Symbol">g</font>. IFN<font face="Symbol">g</font> is    the main activator of macrophages for producing the required cytokines for activating    NK cells and inducing the differentiation of virgins T CD4<SUP>+</SUP> to Th1    lymphocytes. IFN<font face="Symbol">g</font> is also relevant in the control    of <I>Plasmodium chabaudi</I> infection since IFN<font face="Symbol">g</font>    knockout mice developed significantly higher parasitaemia during acute infection    than wild type mice.<SUP>15</SUP> </font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"> The aim of the present work was, therefore,    to evaluate the protective effect against <I>Plasmodium chabaudi </I>infection    in NIH mice after IP injection of viable <I>Lactobacillus casei </I>ssp. <I>rhamnosus</I>;    to determine the effect against malaria parasites lodged in the spleen and evaluate    its correlation with nitric oxide (NO<sup>.</sup>) production. This work was    carried out at the Escuela Nacional de Ciencias Biologicas, IPN, Mexico (ENCB,    IPN), from 2004 to 2005.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Materials and Methods</b></font></p>     <p><font size="2" face="Verdana">Mice. NIH mice, weighing 22 to 25 g (8 to 10    weeks old), were obtained from a random-breed colony (purchased in BIRMEX S.A.    M&eacute;xico D.F.). All normal and infected animals were housed and cared for    according to international guidelines for the caring and use of laboratory animals.    Unnecessary pain was avoided in infected mice and they were painlessly killed    at the end of the experiment. Each experimental group consisted of six mice. The protocol was revised by the Escuela Nacional de Ciencias Biologicas,    Instituto Polit&eacute;cnico Nacional Bioethics Committee.</font></p>     <p><font size="2" face="Verdana"><I>Plasmodium chabaudi chabaudi</I> AS, kindly    donated by Dr. Luis Fabila Castillo from ENCB, IPN, was maintained in mice by    IP injection, with 10<SUP>5 </SUP>parasitized red blood (pRBC) every 10 days.    After three rounds the strain was preserved in liquid N<SUB>2</SUB>.</font></p>     <p><font size="2" face="Verdana"> <I>Parasitemia</I> was evaluated daily in individual    mice on blood smears stained using the Giemsa technique. pRBC cells were counted    in 50 microscopic fields (approximately 10<SUP>4</SUP> red blood cells) when    parasitaemia was incipient, with a total of 200 red blood cells when parasitaemia    was abundant.</font></p>     <p><font size="2" face="Verdana"> <I>Lactobacillus casei </I>ssp.<I> rhamnosus</I>    ATCC 7469. This strain exhibits probiotic properties because it survives in    the gastrointestinal tract, elicits an up-regulation of IFN<font face="Symbol">g</font>    levels, and enhances resistance against parasite infections in mice.<SUP>5</SUP>    The strain was obtained from the strains collection of the Microbiology Department,    ENCB-IPN. It was maintained in a Man Rogosa Sharpe broth (MRS: Difco. Detroit    Mi, EUA) at 35ºC. After 17 hours in the broth, the culture was washed    with PBS pH 7.2 at 8 944 x g for 10 min, and adjusted to 1.8X10<SUP>9</SUP>    viable organisms/0.1 mL in PBS pH 7.2.</font></p>     <p><font size="2" face="Verdana"> <I>Stimulation with Lactic acid bacteria (LAB) and parasite challenge</I>. Two groups of mice were intraperitoneally (IP)    injected with 1.8X10<SUP>9</SUP> viable <I>Lactobacillus casei</I>. The first    group was injected seven days before parasite challenge and the second was inoculated    twice with the same doses of lactobacilli,14 and 7 days before IP injection    with <I>Plasmodium chabaudi</I> 5X10<SUP>4 </SUP>pRBC (day 0). Some mice were    inoculated with PBS only. </font></p>     <p><font size="2" face="Verdana"> Control mice were inoculated with 5X10<SUP>4</SUP>    <I>P. chabaudi</I> pRBC only. When parasitaemia was resolved, three mice from    each group were killed, the spleen was dissected, weighed, and a total cellular    suspension (75 mg/mL) was prepared in PBS pH 7.2 for inoculating IP naive mice    with 0.1 mL.</font></p>     <p><font size="2" face="Verdana"><I>Serum NO</I><sup>.</sup><I> determination</I>.    Blood was obtained from the caudal vein of three mice per group at 0, 7, 10,    12, 14, and 21 days post-infection. It was allowed to clot for 2 hours at 4ºC,    and then centrifuged at 8,944 x g for 10 min. Sera were collected and stored    at –20ºC until used for determination of NO<sup>.</sup>. </font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"> For each serum sample, 50 &#181;l were transferred    to a flat bottom plate, and 50 &#181;L of Greiss reagent were added (25 &#181;L    of 1% sulfanilamide, 25 &#181;L of 0.1% naphtyl-ethylen-diamine (Sigma Chemical    Co., St Louis, MO, EUA) in 2.5% H<SUB>3</SUB>PO<SUB>4</SUB>) and incubated at    room temperature for 15 min. Absorbance was measured at 550 nm (A<SUB>550</SUB>)    using an ELISA reader (Labsystems Multiskan Plus). NO<SUB>2</SUB>- concentrations    were determined using a standard NaNO<SUB>2</SUB> curve<SUB>.</SUB></font></p>     <p><font size="2" face="Verdana"><I>Infection with spleen cells from mice that    recovered from infection with </I>Plasmodium chabaudi chabaudi <I>AS. </I>Group    I mice were inoculated with spleen cells from mice that recovered from an infection    with <I>Plasmodium chabaudi</I>. Group II was inoculated with spleen cells from    mice that recovered from an infection with <I>Plasmodium chabaudi </I>before    being treated once with <I>L. casei</I>; Group III was inoculated with spleen    cells from mice that recovered from an infection with <I>Plasmodium chabaudi    </I>before being treated twice with <I>L. casei</I>. Control mice (Group IV)    were inoculated with 5X10<SUP>4</SUP> <I>P. chabaudi </I>pRBC only. The findings    were confirmed in three repeated trials.</font></p>     <p><font size="2" face="Verdana"> <I>Statistical analysis. </I>Parasitaemia was    analyzed using the U-Mann-Whitney test and serum nitric levels were analyzed    using a two-way ANOVA; <I>p</I>&lt;0.05 values were considered statistically    different.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Results</b></font></p>     <p><font size="2" face="Verdana"><b>Stimulation with Lactic acid bacteria (LAB)    and parasite challenge</b></font></p>     <p><font size="2" face="Verdana">Mice infected with 5X10<SUP>4</SUP> <I>P. chabaudi</I>    pRBC (control group) developed parasitaemia with a prepatent period of 4 days,    patent period of 15 days, and maximum (about 51%) on day nine postinfection.    Mice stimulated once with lactobacilli showed important changes in the early    phase of the <I>P. chabaudi</I> infection<I>, </I>with a prepatent period of    5 days, a patent period of 11 days, and a maximum parasitaemia (36.3%) on day    12 post-infection; on the 7th day post infection, the parasitaemia level was    about 0.4%, whereas in control mice it was about 27.8%. After the peak of parasitaemia,    stimulated mice showed a quick drop in the curve (&lt;10% in 72 hours), while    the control mice reached this level in 120 hours (<a href="#fig01">figure 1</a>).    </font></p>     <p><a name="fig01"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/spm/v48n6/a08fig01.gif"></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font size="2" face="Verdana"> Mice stimulated twice with <I>Lactobacillus    casei</I> and challenged with <I>P. chabaudi </I>showed a prepatent period of    5 days, a patent period of 8 days, and 30% parasitaemia on the 11<SUP>th</SUP>    day, while the control group showed a prepatent period of 3 days, a patent period    of 13 days, and a maximum parasitaemia of 48.5% on day nine post-infection.    These mice maintained minimum parasitaemia levels (&lt;10%) during the first    eight days post-infection while the control mice showed parasitaemia levels    around 40%. After the parasitaemia peak, stimulated mice showed a fast drop    with less than 10% pRBC in 48 hours, whereas the control group maintained the    same level after 5 days (<a href="#fig02">figure 2</a>). </font></p>     <p><a name="fig02"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/spm/v48n6/a08fig02.gif"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><b>Infection with spleen cells from mice that    recovered from <I>Plasmodium chabaudi chabaudi </I>AS infection</b></font></p>     <p><font size="2" face="Verdana">Mice infected with parasites obtained from spleen    cells from mice that recovered from a <I>Plasmodium chabaudi </I>infection (group    I) showed a parasitaemia similar to control mice inoculated with pRBC only (group    IV), with a prepatent period of four days, a patent period of 13 days, and maximum    parasitaemia of 46.6% on the 10<SUP>th</SUP> day. Group II mice inoculated with    spleen cells from mice stimulated once with <I>Lactobacillus casei </I>and challenged    with <I>Plasmodium chabaudi </I>showed a prepatent period of five days, a patent    period of 11 days, and a maximum parasitaemia of 33.5% on the 10<SUP>th</SUP>    day after infection. There was a statistically significant difference (<I>p</I>&lt;0.01)    between the control group and the group of mice inoculated with spleen cells    from mice stimulated twice with <I>Lactobacillus casei </I>before challenging    with <I>Plasmodium chabaudi</I> (group III), the prepatent period was 21 days,    the patent period was seven days, and the maximum parasitaemia was 13.5% on    the 26<SUP>th</SUP> day (<a href="#fig03">figure 3</a>).</font></p>     <p><a name="fig03"></a></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p align="center"><img src="/img/revistas/spm/v48n6/a08fig03.gif"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><b>Serum NO determination</b></font></p>     <p><font size="2" face="Verdana">In the control (group I), a basal level of NO<sup>.</sup>    of 16 &#181;M was observed, which was increasing with the course of infection.    The maximum level reached about 76 &#181;M on day 10 post-infection, coinciding    with the parasitaemia peak, then dropped to the basal level (day 21). Mice stimulated    once with lactobacilli and challenged with <I>P. chabaudi</I> presented about    a 500% increase (92.66 &#181;M) on day 0 (7 days after stimulation); maximum    NO<sup>.</sup> concentration was reached on day 10 (142.3 &#181;M) (<a href="#tab01">table    I</a>). Mice stimulated twice with lactobacilli and challenged with <I>P. chabaudi</I>    showed the highest NO<sup>.</sup> levels, on day 0 they had an increase of more    than 900% (153.3 &#181;M) with respect to the basal, and the maximum NO<sup>.</sup>    level was on day 10 and declined to 64.3 &#181;M on day 21 (<a href="#tab02">table    II</a>). Mice inoculated once and inoculated twice with vehicle (PBS pH 7.2)    had roughly 15 &#181;M of NO<SUB>2</SUB>-.</font></p>     <p><a name="tab01"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/spm/v48n6/a08tab01.gif"></p>     <p>&nbsp;</p>     <p><a name="tab02"></a></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p align="center"><img src="/img/revistas/spm/v48n6/a08tab02.gif"></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Discussion</b></font></p>     <p><font size="2" face="Verdana">Innate immune response is a host's first line    of defense against parasites. It determines the course of an infection, curing,    and dissemination. Innate immune system components are mechanics barriers, cells,    molecules, and cytokines. The IL-12 and IFN<font face="Symbol">g</font> are    cytokines which participate in regulating the innate immune response, and are    key to the induction of the adaptative immune response. Macrophages produce    IL-12 in response to several microorganisms. IL-12 stimulate the synthesis of    IFN<font face="Symbol">g</font> by NK and T lymphocytes which, in turn, activates    more macrophages for destroying the microorganisms. One macrophage destroyer    mechanisms is the synthesis of reactive metabolites of oxygen and NO<sup>.</sup>.    IFN<font face="Symbol">g</font> activates the transcription of genes that codify    oxydase and nitric oxide synthase enzymes. </font></p>     <p><font size="2" face="Verdana"> Since the discovery that mammalian cells produce    NO<sup>.</sup>, considerable attention has been focused on its role in the cell    of killing microbes. Recently, macrophages, neutrophils, and mast cells have all been shown to be major producers of this molecule. NO<sup>.</sup>    is a gaseous water and lipid soluble molecule that regulates several physiological    responses in the cardiovascular and nervous systems. Immune and tissue cells    produce NO<sup>.</sup> via the inducible nitric oxide synthase (iNOS) pathway    in response to infectious and injurious agents.<SUP>16,17</SUP> </font></p>     <p><font size="2" face="Verdana"> Some probiotics, such as the <I>Lactobacillus    </I>and <I>Bifidobacteria</I> species, have been found to induce innate immune    mechanisms, including enhancement of epithelial barrier function in the intestine,    activation of NF-<font face="Symbol">k</font>B and cytokine production in monocytes    and natural killer cells, and induction of phagocytic activity in neutrophils.<SUP>1,2</SUP>    Korhonen<SUP>18</SUP> investigated the effects of <I>Lactobacillus rhamnosus    GG</I> probiotic bacteria and found iNOS expression and NO<sup>.</sup> production    in macrophages in response to <I>Lactobacillus rhamnosus</I> GG and IFN<font face="Symbol">g</font>,    suggesting that this probiotic has immunomodulatory effects. </font></p>     <p><font size="2" face="Verdana"> It has been shown that NO<sup>.</sup> is produced    during the infection of mice with <I>Plasmodium cahabaudi </I>AS. <I>In vivo    </I>production of NO<sup>.</sup> during a <I>P. chabaudi </I>AS infection in    NIH mice, measured as nitrate in the serum of infected mice, showed a sharp    peak of production around peak parasitaemia; treatment of mice with L-NMM (L-Ng-monomehyl    arginine), an inhibitor of NO<sup>.</sup> production, produced a detectable    exacerbation of the peak parasitaemia.<SUP>19,20</SUP> </font></p>     <p><font size="2" face="Verdana"> In the present work, it is evident that <I>L.    casei </I>enhances innate resistance to <I>Plasmodium chabaudi,</I> as was showed    by lower parasitaemia in mice previously stimulated once or twice with lactobacilli    than the control. Stimulated mice had larger prepatent periods and lower parasitaemia    than the control (<a href="#fig01">figures 1</a> and <a href="#fig02">2</a>).    </font></p>     <p><font size="2" face="Verdana"> Parasites recovered from the spleens of mice    previously stimulated with <I>Lactobacillus casei </I>and challenged with <I>Plasmodium    chabaudi</I> kept their infective capacity, but the parasitemia was delayed    and less intense than in control mice, suggesting that parasites were affected    by the non-specific mechanism elicited by viable lactobacilli, and that the    spleen plays an important role in the elimination of malaria parasites (<a href="#fig03">figure    3</a>). The precise regulatory mechanisms of iNOS expression in vivo and the    physiologic role of NO<sup>.</sup> in different organs during lethal and non-lethal    <I>P</I>. <I>chabaudi </I>AS infection are not yet known (Jacobs <I>et al</I>.).<SUP>21</SUP>    Moreover, the tissue site of NO<sup>.</sup> production, that is spleen <I>vs.</I>    liver, appears to be critical and correlates with resistance <I>vs.</I> susceptibility    to <I>P. chabaudi</I> AS, respectively. </font></p>     <p><font size="2" face="Verdana"> Host phagocytic cell activity may play an important    role in the control of <I>P. chabaudi</I> AS erythrocytic stages early in the    infection. Legorreta-Herrera<I> et al.,</I><SUP>22</SUP> could transfer protection    against <I>Plasmodium chabaudi chabaudi</I> in T cells depleted mice with irradiated    spleen cells from hyper immune mice. Furthermore, Mota<I> et al,</I><SUP>23</SUP>    observed phagocytosis by macrophages of parasitized erythrocytes <I>in vitro</I>    in acute <I>Plasmodium chabaudi</I> infection. Jacobs <I>et al</I><SUP>21</SUP>    investigated the production and function of NO<sup>.</sup> during the early    phase of blood stage infection with <I>Plasmodium chabaudi</I> AS in two inbred    strains of mice that differ in resistance levels to this parasite. They found    that the resistant C57BL/6 mice, which clear the infection by week four, have    higher iNOS mRNA in the spleen than susceptible A/J mice. In contrast, A/J mice    have significantly increased levels of iNOS mRNA in the liver later in the infection,    just before death occurs. Furthermore, splenic macrophages recovered from resistant    mice produced significantly higher levels of nitrite (NO<SUB>2</SUB>-) in response    to LPS than macrophages from susceptible mice. Increased levels of NO<sup>.</sup>    were only detected in the serum of resistant mice at the time of peak parasitaemia.    Treatment with the iNOS inhibitor, aminoguanidine, reduced NO<sup>.</sup> levels    in the serum of resistant mice and eliminated resistance of this host to <I>Plasmodium    chabaudi</I> AS without affecting parasitaemia. These results demonstrate that    the ability to produce high amounts of NO<sup>.</sup> early during the infection    with blood stages of <I>Plasmodium chabaudi</I> AS correlates with resistance,    but that NO<sup>.</sup> may not be involved in parasite killing. However, Rockett    <I>et al</I>.,<SUP>16</SUP> showed that a saturated solution of NO<sup>.</sup>    did not inhibit <I>Plasmodium falciparum</I> growth, but two oxidation products    of NO<sup>.</sup> (nitrite and nitrate ions) were toxic to the parasite. </font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"> In conclusion, the results presented in this    work suggest that <I>Lactobacillus casei</I> ssp.<I> rhamnosus </I>ATCC 7469,    when given viable by IP injection, enhances a systemic, non-specific protection    with an increase of NO<sup>.</sup> production (<a href="#tab01">tables I</a>    and <a href="#tab02">II</a>). That mechanism probably includes phagocytic activity    of macrophages that help to control the early stage of <I>P. chabaudi</I>    infection, to the erythrocytic phases and the parasites lodged in the spleen.</font></p>     <p><font size="2" face="Verdana"><b>Acknowledgments</b></font></p>     <p><font size="2" face="Verdana">Thanks to the Instituto Polit&eacute;cnico Nacional,    which supported this work through the: CGPI- 20010470 grant.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>References</b></font></p>     <!-- ref --><p><font size="2" face="Verdana">1. Perdig&oacute;n G, Maldonado-Galdeano C, Valdez    JC, Medici M. Interaction of lactic acid bacteria with the gut immune system.    Eur J Clin Nutr 2002; 56: S21-S26. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223813&pid=S0036-3634200600060000800001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">2. Gill H S. Stimulation of the immune system    by lactic cultures. Int Dairy J 1998; 8: 535-534. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223814&pid=S0036-3634200600060000800002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">3. Christensen H, Frokiaer H, Pestka J J. Lactobacilli    differentially modulate expression of cytokines and maturation surface markers    in murine dendritic cells. J Immunol 2002;168: 171-178. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223815&pid=S0036-3634200600060000800003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">4. Perdig&oacute;n G, Vinti&ntilde;i E, &Aacute;lvarez    S, Medina M, Medici M. Study of the possible mechanisms involved in the mucosal    immune system activation by lactic acid bacteria. J Dairy Sci 1999; 82: 1108-1114.    </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223816&pid=S0036-3634200600060000800004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">5. Bautista-Garfias CR, Ixta O, Ordu&ntilde;a    M, Mart&iacute;nez F, Aguilar B, Cort&eacute;s A. Enhancement of resistance    in mice treated with <I>Lactobacillus casei: </I>Effect on <I>Trichinella spiralis</I>    infection. Vet Parasitol 1999; 80: 25-260. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223817&pid=S0036-3634200600060000800005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">6. Matsuzaki T. Immuno modulation by treatment    with <I>Lactobacillus casei</I> strain Shirota. Int J Food Microbiol 1998; 41:    133-140. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223818&pid=S0036-3634200600060000800006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">7. Ogawa M, Shimizu K, Nomoto K, Tanaka R, Yamasaki    S, Takeda T, <I>et al</I>. Inhibition of in vitro growth of Shiga toxin-producing    <I>Escherichia coli </I>O157:H7 by probiotic <I>Lactobacillus</I> strains due    to production of lactic acid. Int J Food Microbiol 2001;68: 135-140. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223819&pid=S0036-3634200600060000800007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">8. Perdig&oacute;n G, Nader de Mac&iacute;as    ME, &Aacute;lvarez S, Oliver G, de Ruiz-Holgado AA. Prevention of gastrointestinal    infection using immunobiological methods with milk fermented with <I>Lactobacillus    casei</I> and <I>Lactobacillus acidophilus.</I> J Dairy Res 1990; 57: 255-264.    </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223820&pid=S0036-3634200600060000800008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">9. Hudault S, Li&eacute;vin V, Bernet-Camard    MF, Servin AL. Antagonistic activity exerted <I>in vitro</I> and <I>in vivo</I>    by <I>Lactobacillus casei</I> (strain GG) against <I>Salmonella typhimurium</I>    C5 infection. Appl Environ Microbiol 1997; 63: 513-518. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223821&pid=S0036-3634200600060000800009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">10. Wagner R D, Pierson C, Warner T, Dohnalek    M, Farmer J, Roberts L, <I>et al</I>. Biotherapeutic effects of probiotic bacteria    on candidiasis in immuno-deficient mice. Infect Immun 1997; 65: 4165-4172. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223822&pid=S0036-3634200600060000800010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">11. Isolauri E, Joensu J, Suomalainen H, Loumala    M, Vesikari T. Improved immunogenicity of oral Dx RRV reassortant rotavirus    vaccine by <I>Lactobacillus casei</I> GG. Vaccine 1995;13: 310-312. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223823&pid=S0036-3634200600060000800011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">12. Bautista-Garfias CR, Ixta-Rodr&iacute;guez    O, Mart&iacute;nez-G&oacute;mez F, L&oacute;pez MG, Aguilar-Figueroa BR. Effect    of viable or dead <I>Lactobacillus casei </I>organisms given orally to mice    on resistance against <I>Trichinella spiralis</I> infection. Parasite 2001;    8: 226-228. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223824&pid=S0036-3634200600060000800012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">13. Kato I, Tanaka K, Yokokura T. Lactic acid    bacterium potently induces the production of interleukin-12 and interferon-g    by mouse splenocytes. Int J Immunopharmacol 1999; 21:121-131. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223825&pid=S0036-3634200600060000800013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">14. Takagi A, Matsuzaki T, Sato M, Nomoto K,    Morotom M, Yokokura T. Enhancement of natural killer cytotoxity delayed murine    carcinogenesis by a probiotic microorganism. Carcinogenesis 2001; 22: 599-605.    </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223826&pid=S0036-3634200600060000800014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">15. Su Z, Stevenson M. Central role of endogenous    gamma interferon in protective immunity against blood-stage <I>Plasmodium chabaudi    </I>AS infection. Infect Immun 2000; 68: 4399-4406. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223827&pid=S0036-3634200600060000800015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">16. Rockett K A, Awburn MM, Cowden WB, Clark    I A. Killing of <I>Plasmodium falciparum</I> in vitro by nitric oxide derivatives.    Infect Immun 1991; 59: 3280-3283. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223828&pid=S0036-3634200600060000800016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">17. Fristche G, Larcher C, Schennach H, Weiss    G. Regulatory interactions between iron and nitric oxide metabolism for immune    defense against <I>Plasmodium falciparum </I>infection. J Infect Dis 2001; 183:1388-1394.    </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223829&pid=S0036-3634200600060000800017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">18. Korhonen R, Korpela R, Saxelin M, M&auml;ki    M, Kankaanranta H, Moilanen E. Induction of nitric oxide by probiotic Lactobacillus    rhamnosus GG in J774 macrophages and human T84 intestinal epthelial cells. Inflammation    2001; 25: 223-237. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223830&pid=S0036-3634200600060000800018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">19. Taylor-Robinson AW, Phillips RS, Severn A,    Moncada S, Liew FY. The role of TH1 and Th2 cells cells uin a rodent malaria    infection. Science 1993; 260:1931-1934. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223831&pid=S0036-3634200600060000800019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">20. Phillips RS, Mathers KM, Taylor-Robinson    AW. T cells in immunity to Plasmodium chabaudi chabaudi operation and regulation    of differente pathways of protection. Res Immunol 1994; 145: 406-412. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223832&pid=S0036-3634200600060000800020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">21. Jacobs P, Radzioch D, Stevenson MM. Nitric    oxide expression in the spleen, but not in the liver, correlates with to blood-stage    malaria in mice. J Immunol 1995; 155: 5306-5313. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223833&pid=S0036-3634200600060000800021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">22. Legorreta-Herrera M, Fiallos-Leon C, Barr&oacute;n-Cedillo    L, Mart&iacute;nez-G&oacute;mez F, Cuevas-Foster M, Favila-Castillo L. Anti-Thy-1    treated and irradiated spleen cells from BALB/cX C57BL/6)F1 mice infected with    <I>Plasmodium chabaudi chabaudi</I> can transfer protection into irradiated    hosts. Parasite Immunol 1993; 15: 143-151. </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223834&pid=S0036-3634200600060000800022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">23. Mota MM, Brown KN, Holder AA, Jarra W. Acute    <I>Plasmodium chabaudi chabaudi</I> malaria infection induces antibodies which    bind to the surfaces of parasitized erythrocytes and promote their phagocytosis    by macrophages in vitro. Infect Immun 1998; 66: 4080-4086.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9223835&pid=S0036-3634200600060000800023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p>&nbsp;</p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">Received on: February 23, 2006    <br>   Accepted on: August 14, 2006</font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana">Address reprint request to: Dr. Federico Mart&iacute;nez    G&oacute;mez. Departamento de Parasitolog&iacute;a, Escuela Nacional de Ciencias    Biol&oacute;gicas, Instituto Polit&eacute;cnico Nacional. Carpio y Plan de Ayala    s/n Col. Sto. Tom&aacute;s. 11340 M&eacute;xico, DF, M&eacute;xico. Email: <a href="mailto:f_mar07@yahoo.com.mx">f_mar07@yahoo.com.mx</a>,    <a href="mailto:fmartinezg@ipn.mx">fmartinezg@ipn.mx</a></font></p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perdigón]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Maldonado-Galdeano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Valdez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Medici]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Interaction of lactic acid bacteria with the gut immune system]]></article-title>
<source><![CDATA[Eur J Clin Nutr]]></source>
<year>2002</year>
<volume>56</volume>
<page-range>S21-S26</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gill]]></surname>
<given-names><![CDATA[H S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Stimulation of the immune system by lactic cultures]]></article-title>
<source><![CDATA[Int Dairy J]]></source>
<year>1998</year>
<volume>8</volume>
<page-range>535-534</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Frokiaer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pestka]]></surname>
<given-names><![CDATA[J J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>2002</year>
<volume>168</volume>
<page-range>171-178</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perdigón]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vintiñi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Medici]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Study of the possible mechanisms involved in the mucosal immune system activation by lactic acid bacteria]]></article-title>
<source><![CDATA[J Dairy Sci]]></source>
<year>1999</year>
<volume>82</volume>
<page-range>1108-1114</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bautista-Garfias]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Ixta]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Orduña]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Enhancement of resistance in mice treated with Lactobacillus casei: Effect on Trichinella spiralis infection]]></article-title>
<source><![CDATA[Vet Parasitol]]></source>
<year>1999</year>
<volume>80</volume>
<page-range>25-260</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matsuzaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immuno modulation by treatment with Lactobacillus casei strain Shirota]]></article-title>
<source><![CDATA[Int J Food Microbiol]]></source>
<year>1998</year>
<volume>41</volume>
<page-range>133-140</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogawa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nomoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Yamasaki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Takeda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Inhibition of in vitro growth of Shiga toxin-producing Escherichia coli O157: H7 by probiotic Lactobacillus strains due to production of lactic acid]]></article-title>
<source><![CDATA[Int J Food Microbiol]]></source>
<year>2001</year>
<volume>68</volume>
<page-range>135-140</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perdigón]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nader de Macías]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Oliver]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[de Ruiz-Holgado]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevention of gastrointestinal infection using immunobiological methods with milk fermented with Lactobacillus casei and Lactobacillus acidophilus]]></article-title>
<source><![CDATA[J Dairy Res]]></source>
<year>1990</year>
<volume>57</volume>
<page-range>255-264</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hudault]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Liévin]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bernet-Camard]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Servin]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antagonistic activity exerted in vitro and in vivo by Lactobacillus casei (strain GG) against Salmonella typhimurium C5 infection]]></article-title>
<source><![CDATA[Appl Environ Microbiol]]></source>
<year>1997</year>
<volume>63</volume>
<page-range>513-518</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[R D]]></given-names>
</name>
<name>
<surname><![CDATA[Pierson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Warner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dohnalek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Farmer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Biotherapeutic effects of probiotic bacteria on candidiasis in immuno-deficient mice]]></article-title>
<source><![CDATA[Infect Immun]]></source>
<year>1997</year>
<volume>65</volume>
<page-range>4165-4172</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isolauri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Joensu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Suomalainen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Loumala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vesikari]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Improved immunogenicity of oral Dx RRV reassortant rotavirus vaccine by Lactobacillus casei GG]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>1995</year>
<volume>13</volume>
<page-range>310-312</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bautista-Garfias]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Ixta-Rodríguez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Gómez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar-Figueroa]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of viable or dead Lactobacillus casei organisms given orally to mice on resistance against Trichinella spiralis infection]]></article-title>
<source><![CDATA[Parasite]]></source>
<year>2001</year>
<volume>8</volume>
<page-range>226-228</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yokokura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Lactic acid bacterium potently induces the production of interleukin-12 and interferon-g by mouse splenocytes]]></article-title>
<source><![CDATA[Int J Immunopharmacol]]></source>
<year>1999</year>
<volume>21</volume>
<page-range>121-131</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takagi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuzaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nomoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Morotom]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yokokura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Enhancement of natural killer cytotoxity delayed murine carcinogenesis by a probiotic microorganism]]></article-title>
<source><![CDATA[Carcinogenesis]]></source>
<year>2001</year>
<volume>22</volume>
<page-range>599-605</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection]]></article-title>
<source><![CDATA[Infect Immun]]></source>
<year>2000</year>
<volume>68</volume>
<page-range>4399-4406</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rockett]]></surname>
<given-names><![CDATA[K A]]></given-names>
</name>
<name>
<surname><![CDATA[Awburn]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Cowden]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[I A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Killing of Plasmodium falciparum in vitro by nitric oxide derivatives]]></article-title>
<source><![CDATA[Infect Immun]]></source>
<year>1991</year>
<volume>59</volume>
<page-range>3280-3283</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fristche]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Larcher]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schennach]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Regulatory interactions between iron and nitric oxide metabolism for immune defense against Plasmodium falciparum infection]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2001</year>
<volume>183</volume>
<page-range>1388-1394</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Korhonen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Korpela]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Saxelin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mäki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kankaanranta]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Moilanen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Induction of nitric oxide by probiotic Lactobacillus rhamnosus GG in J774 macrophages and human T84 intestinal epthelial cells]]></article-title>
<source><![CDATA[Inflammation]]></source>
<year>2001</year>
<volume>25</volume>
<page-range>223-237</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor-Robinson]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Severn]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Moncada]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Liew]]></surname>
<given-names><![CDATA[FY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The role of TH1 and Th2 cells cells uin a rodent malaria infection]]></article-title>
<source><![CDATA[Science]]></source>
<year>1993</year>
<volume>260</volume>
<page-range>1931-1934</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Mathers]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor-Robinson]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[T cells in immunity to Plasmodium chabaudi chabaudi operation and regulation of differente pathways of protection]]></article-title>
<source><![CDATA[Res Immunol]]></source>
<year>1994</year>
<volume>145</volume>
<page-range>406-412</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Radzioch]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nitric oxide expression in the spleen, but not in the liver, correlates with to blood-stage malaria in mice]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>1995</year>
<volume>155</volume>
<page-range>5306-5313</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Legorreta-Herrera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fiallos-Leon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Barrón-Cedillo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Gómez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cuevas-Foster]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Favila-Castillo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Anti-Thy-1 treated and irradiated spleen cells from BALB/cX C57BL/6)F1 mice infected with Plasmodium chabaudi chabaudi can transfer protection into irradiated hosts]]></article-title>
<source><![CDATA[Parasite Immunol]]></source>
<year>1993</year>
<volume>15</volume>
<page-range>143-151</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mota]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Holder]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Jarra]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Acute Plasmodium chabaudi chabaudi malaria infection induces antibodies which bind to the surfaces of parasitized erythrocytes and promote their phagocytosis by macrophages in vitro]]></article-title>
<source><![CDATA[Infect Immun]]></source>
<year>1998</year>
<volume>66</volume>
<page-range>4080-4086</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
